Cibus, Inc. reported its financial results for the second quarter ended June 30, 2025. The company announced a net loss of $25.4 million, which widened by 2.0% from the prior year period. Revenue for Q2 2025 was $0.9 million, falling short of analyst estimates.
The company is streamlining its operational focus on Rice herbicide tolerance traits and partner-funded sustainable ingredients programs, with initiatives expected to reduce annual cash usage to approximately $30 million by 2026. Commercialization of Rice HT1 and HT3 traits is on track for initial launch in Latin America in 2027 and the U.S. in 2028, with potential annual accessible royalties over $200 million.
Peter Beetham, Interim CEO, stated that the company remains focused on its core priorities and is making progress toward initial commercial launch of priority traits. Cibus also signed a collaboration agreement with Colombian Rice seed company Semillano and completed delivery of three germplasm lines with the HT3 trait to an existing Rice customer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.